Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.55
DRTX's Cash to Debt is ranked higher than
54% of the 1276 Companies
in the Global Biotechnology industry.

( Industry Median: 72.05 vs. DRTX: 0.55 )
DRTX' s 10-Year Cash to Debt Range
Min: 0.55   Max: No Debt
Current: 0.55

Equity to Asset -0.20
DRTX's Equity to Asset is ranked higher than
52% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. DRTX: -0.20 )
DRTX' s 10-Year Equity to Asset Range
Min: -0.2   Max: -0.2
Current: -0.2

F-Score: 3
Z-Score: -2.47
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -679.94
DRTX's Operating margin (%) is ranked higher than
60% of the 1044 Companies
in the Global Biotechnology industry.

( Industry Median: -85.54 vs. DRTX: -679.94 )
DRTX' s 10-Year Operating margin (%) Range
Min: 0   Max: 0
Current: -679.94

Net-margin (%) -730.11
DRTX's Net-margin (%) is ranked higher than
59% of the 1044 Companies
in the Global Biotechnology industry.

( Industry Median: -80.82 vs. DRTX: -730.11 )
DRTX' s 10-Year Net-margin (%) Range
Min: 0   Max: 0
Current: -730.11

ROE (%) -375.05
DRTX's ROE (%) is ranked higher than
50% of the 1162 Companies
in the Global Biotechnology industry.

( Industry Median: -32.57 vs. DRTX: -375.05 )
DRTX' s 10-Year ROE (%) Range
Min: -1188.24   Max: -150.73
Current: -375.05

-1188.24
-150.73
ROA (%) -81.97
DRTX's ROA (%) is ranked higher than
57% of the 1282 Companies
in the Global Biotechnology industry.

( Industry Median: -26.11 vs. DRTX: -81.97 )
DRTX' s 10-Year ROA (%) Range
Min: -196.48   Max: -66.57
Current: -81.97

-196.48
-66.57
ROC (Joel Greenblatt) (%) -6588.33
DRTX's ROC (Joel Greenblatt) (%) is ranked higher than
57% of the 1245 Companies
in the Global Biotechnology industry.

( Industry Median: -373.92 vs. DRTX: -6588.33 )
DRTX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -12758.41   Max: -6067.31
Current: -6588.33

-12758.41
-6067.31
» DRTX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

DRTX Guru Trades in

Q1 2014

DRTX Guru Trades in Q1 2014

Jim Simons 60,300 sh (New)
» More
Q2 2014

DRTX Guru Trades in Q2 2014

Jim Simons 66,200 sh (+9.78%)
» More
Q3 2014

DRTX Guru Trades in Q3 2014

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with DRTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 63.58
DRTX's P/S is ranked higher than
59% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 31.20 vs. DRTX: 63.58 )
DRTX' s 10-Year P/S Range
Min: 34.61   Max: 63.58
Current: 63.58

34.61
63.58
Current Ratio 1.36
DRTX's Current Ratio is ranked higher than
56% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.61 vs. DRTX: 1.36 )
DRTX' s 10-Year Current Ratio Range
Min: 0.65   Max: 5.88
Current: 1.36

0.65
5.88
Quick Ratio 1.26
DRTX's Quick Ratio is ranked higher than
57% of the 1267 Companies
in the Global Biotechnology industry.

( Industry Median: 4.33 vs. DRTX: 1.26 )
DRTX' s 10-Year Quick Ratio Range
Min: 0.65   Max: 5.88
Current: 1.26

0.65
5.88
Days Sales Outstanding 6.95
DRTX's Days Sales Outstanding is ranked higher than
97% of the 1365 Companies
in the Global Biotechnology industry.

( Industry Median: 111.38 vs. DRTX: 6.95 )
DRTX' s 10-Year Days Sales Outstanding Range
Min: 0   Max: 0
Current: 6.95

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) -10.20
DRTX's Earnings Yield (Greenblatt) is ranked higher than
61% of the 1260 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. DRTX: -10.20 )
DRTX' s 10-Year Earnings Yield (Greenblatt) Range
Min: -10.2   Max: 0
Current: -10.2

-10.2
0

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:DTA.Germany,
Durata Therapeutics Inc was incorporated under the laws of the State of Delaware on November 4, 2009. The Company, along with its subsidiaries, is a development stage pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. The Company recently completed two global Phase 3 clinical trials with its lead product candidate, dalbavancin, for the treatment of patients with acute bacterial skin and skin structure infections, or ABSSSI. Dalbavancin is an intravenous antibiotic product candidate designed for once-weekly dosing.
» More Articles for DRTX

Headlines

Articles On GuruFocus.com
Three Stocks With Massive Insider Buying Sep 03 2014 
Ttreatment for skin Aug 05 2012 

More From Other Websites
Actavis Launches U.S. Generic Specialty Injectable Portfolio Jan 20 2015
ArQule (ARQL) Shows Strength: Stock Adds 6 % in Session Nov 18 2014
Esperion Therapeutics (ESPR) Jumps: Stock Moves Up 6.4% Nov 18 2014
DURATA THERAPEUTICS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement,... Nov 17 2014
Actavis Successfully Completes Durata Therapeutics, Inc. Tender Offer Nov 17 2014
Actavis Successfully Completes Durata Therapeutics, Inc. Tender Offer Nov 17 2014
DURATA THERAPEUTICS, INC. Financials Nov 15 2014
DURATA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Nov 13 2014
DURATA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report Nov 07 2014
Actavis and Durata Therapeutics Receive U.S. FTC Clearance for Actavis' Proposed Acquisition of... Oct 31 2014
Actavis and Durata Therapeutics Receive U.S. FTC Clearance for Actavis' Proposed Acquisition of... Oct 31 2014
INVESTOR ALERT: Levi & Korsinsky, LLP Launches Investigation of the Board of Directors of Durata... Oct 14 2014
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of Durata Therapeutics, Inc. in... Oct 11 2014
DURATA SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Durata Therapeutics... Oct 10 2014
DURATA THERAPEUTICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of... Oct 10 2014
SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Durata... Oct 10 2014
Harwood Feffer LLP Announces Investigation of Durata Therapeutics, Inc. Oct 09 2014
DURATA THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Oct 09 2014
Lifshitz & Miller Law Firm Announces Investigation of Altair Nanotechnologies, Inc., CareFusion,... Oct 07 2014
INVESTOR ALERT: The Law Offices of Vincent Wong Investigates the Board of Directors of Durata... Oct 07 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK